GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Debt-to-Equity

Daiichinkyo Co (Daiichinkyo Co) Debt-to-Equity : 0.06 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Debt-to-Equity?

Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3 Mil. Daiichinkyo Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $676 Mil. Daiichinkyo Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $11,268 Mil. Daiichinkyo Co's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Daiichinkyo Co's Debt-to-Equity or its related term are showing as below:

DSNKY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07   Med: 0.17   Max: 0.43
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Daiichinkyo Co was 0.43. The lowest was 0.07. And the median was 0.17.

DSNKY's Debt-to-Equity is ranked better than
76.99% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs DSNKY: 0.07

Daiichinkyo Co Debt-to-Equity Historical Data

The historical data trend for Daiichinkyo Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Debt-to-Equity Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.15 0.12 0.10 0.06

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.07 0.07 0.06

Competitive Comparison of Daiichinkyo Co's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Debt-to-Equity falls into.


Daiichinkyo Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Daiichinkyo Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.663 + 676.244) / 11268.114
=0.06

Daiichinkyo Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.663 + 676.244) / 11268.114
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co  (OTCPK:DSNKY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Daiichinkyo Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Debt-to-Equity
Comparable Companies
TSE:4519 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
DSKYF:USA 4568:Japan D4S:Germany
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.